{"analyses":[{"ciLowerLimit":"-7.44","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.72","estimateComment":"A difference in least square means less than 0 favors the Osimertinib (AZD9291) + Chemo treatment arm.","groupDescription":"The analysis was performed using analysis of covariance with baseline tumor size and time from baseline scan to randomization as covariates and with factors race (Chinese/Asian vs. Non-Chinese/Asian vs. Non-Asian), WHO performance status (0 vs. 1), and method used for tissue testing (central vs. local).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1067","paramType":"Least Square Mean Difference","paramValue":"-3.36","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-53.75","upperLimit":"-47.78","value":"-50.77"},{"groupId":"OG001","lowerLimit":"-50.39","upperLimit":"-44.43","value":"-47.41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"276"}],"units":"Participants"}],"description":"Depth of Response (percent change from Baseline in tumor diameter) is defined as the relative percent change in the sum of the longest diameters of RECIST 1.1 target lesions (TL) at the nadir in the absence of new lesions or progression of non-target lesions (NTL) compared to baseline. The best percentage change in TL size is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction. Tumor assessments of the chest and abdomen (including the entire liver and both adrenal glands) were performed using RECIST 1.1 by the investigator on images from CT (preferred) or MRI with IV contrast.","dispersionType":"95% Confidence Interval","groups":[{"description":"Osimertinib (AZD9291) 80 mg in combination with pemetrexed (500 mg/m2) plus either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles for 4 cycles, followed by Osimertinib (AZD9291) 80 mg QD with Pemetrexed maintenance (500 mg/m2) Q3W","id":"OG000","title":"Randomized: AZD9291 + Chemo"},{"description":"Osimertinib (AZD9291) 80mg QD.","id":"OG001","title":"Randomized: AZD9291"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Full Analysis Set, includes all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 33 months after the first patient is randomized.","title":"Depth of Response (Percent Change From Baseline in Tumor Diameter) (Randomized Component)","type":"SECONDARY","unitOfMeasure":"Percent change from baseline"}